ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

COG Begins Phase III Trial To Prevent Hearing Loss

May 30, 2008

In Brief: DeVita On Laetrile Hit List; Hammer Removal As Panel Head Sought By Love Canal Activist

November 6, 1981

Environmental Carcinogenesis Seen As Next Big Growth Field; NCA Hears Problems, Priorities

October 31, 1975

ODAC Recommends FDA Approval For Grain Tumor Implant

June 21, 1996

CCOP Letters Of Intent Reach 232; Frelick Experts 80-90 Percent Of them To Qualify For Applications

September 3, 1982